← Leaderboards
Lydia Pecker
Johns Hopkins University
$1,946,939
Attributed
$3,959,198
Total exposure
3
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1M · FY2018–25$2M$1.5M$1M$500K$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,959,198 · 3
By mechanism
U01$2,519,263 · 1
K23$1,194,311 · 1
R21$245,624 · 1
Top collaborators
- Michael Rutledge Debaun3 shared
- Courtney D Fitzhugh3 shared
- Debra L Friedman3 shared
- Sophie M Lanzkron2 shared
Most similar at Johns Hopkins University
Same institution · by research overlap
- Jiangyang Zhang$12,845,824
- Frances J Northington$9,523,922
- Jennifer Kim Lee$3,860,170
- Ben H Park$14,510,999
- Alison P Klein$15,423,583
Others in their field
Other Emerging Leaders on “Sickle Cell Anemia”
- Dawn C Ward · University Of California Los Angeles$7,282,377
- Hyacinth Idu Hyacinth · University Of Cincinnati$6,507,943
- Angelo D'alessandro · University Of Colorado Denver$6,184,587
- Soumitri Sil · Emory University$6,137,743
- Julie Makani · Muhimbili University/ Allied Hlth Scis$5,942,050
- Rachel G Greenberg · Duke University$4,501,880
Research focus
Sickle Cell AnemiaFertilityCessation Of LifeCohortAdultOrganReproductiveHydroxyureaPositioning AttributeCross-Sectional StudiesEvaluationGirlsFundingMethodologyHemolytic AnemiaOvarian ReserveHematologistAffectBiological MarkersFemaleMultiorgan InjuryChildOvaryWoman
Grant awards (12)
Clinical and genetic risk factors associated with adverse long-term health outcomes after curative therapies in individuals with sickle cell disease$841,945
U01 · FY2025 · HL
Clinical and genetic risk factors associated with adverse long-term health outcomes after curative therapies in individuals with sickle cell disease$827,619
U01 · FY2024 · HL
OVARIAN RESERVE IN POST-MENARCHAL FEMALES WITH SICKLE CELL ANEMIA$198,065
K23 · FY2024 · HL · contact PI
Clinical and genetic risk factors associated with adverse long-term health outcomes after curative therapies in individuals with sickle cell disease$849,699
U01 · FY2023 · HL
OVARIAN RESERVE IN POST-MENARCHAL FEMALES WITH SICKLE CELL ANEMIA$198,065
K23 · FY2023 · HL · contact PI
OVARIAN RESERVE IN POST-MENARCHAL FEMALES WITH SICKLE CELL ANEMIA$198,065
K23 · FY2022 · HL · contact PI
OVARIAN RESERVE IN POST-MENARCHAL FEMALES WITH SICKLE CELL ANEMIA$151,200
K23 · FY2022 · HL · contact PI
OVARIAN RESERVE IN POST-MENARCHAL FEMALES WITH SICKLE CELL ANEMIA$53,959
K23 · FY2022 · HL · contact PI
OVARIAN RESERVE IN POST-MENARCHAL FEMALES WITH SICKLE CELL ANEMIA$198,065
K23 · FY2021 · HL · contact PI
OVARIAN RESERVE IN POST-MENARCHAL FEMALES WITH SICKLE CELL ANEMIA$196,892
K23 · FY2020 · HL · contact PI
Anti-Mullerian Hormone in the Female Participants of the Multi-Center Study of Hydroxyurea$122,812
R21 · FY2019 · HL
Anti-Mullerian Hormone in the Female Participants of the Multi-Center Study of Hydroxyurea$122,812
R21 · FY2018 · HL